- Market Capitalization, $K 419,725
- Shares Outstanding, K 7,287
- Annual Sales, $ 32,960 K
- Annual Income, $ 20,050 K
- 60-Month Beta 1.30
- Price/Sales 12.92
- Price/Cash Flow 18.91
- Price/Book 4.17
|Period||Period Low||Period High||Performance|
| || |
-4.73 (-7.59%)since 05/24/19
| || |
-7.41 (-11.40%)since 03/22/19
| || |
+13.69 (+31.18%)since 06/22/18
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed...
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
The U.S. labor market is the major driver of the bull run, which is more than a decade old.
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.